| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6211205 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6150383 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6329404 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US7538125 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6303640 | TAKEDA PHARMS USA | Pharmaceutical composition |
Aug, 2016
(7 years ago) | |
| US7700128 | TAKEDA PHARMS USA | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
Jan, 2027
(2 years from now) | |
| US8071130 | TAKEDA PHARMS USA | Solid preparation |
Jun, 2028
(4 years from now) | |
Duetact is owned by Takeda Pharms Usa.
Duetact contains Glimepiride; Pioglitazone Hydrochloride.
Duetact has a total of 7 drug patents out of which 5 drug patents have expired.
Expired drug patents of Duetact are:
- US6211205
- US6150383
- US6329404
- US7538125
- US6303640
Duetact was authorised for market use on 28 July, 2006.
Duetact is available in tablet;oral dosage forms.
Duetact can be used as as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes.
The generics of Duetact are possible to be released after 08 June, 2028.
Drugs and Companies using GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 July, 2006
Treatment: As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes
Dosage: TABLET;ORAL
DUETACT family patents
